Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
DOI:
https://doi.org/10.2340/actadv.v103.11657Keywords:
JAK inhibitors, acneiform lesions, drug-induced acne, JAKne, acneAbstract
Abstract is missing (Short communication)
Downloads
References
Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context 2020; 9: 2020-8-5.
https://doi.org/10.7573/dic.2020-8-5 DOI: https://doi.org/10.7573/dic.2020-8-5
Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. Allergol Int 2022; 71: 40-46.
https://doi.org/10.1016/j.alit.2021.10.004 DOI: https://doi.org/10.1016/j.alit.2021.10.004
Wood H, Chandler A, Nezamololama N, Papp K, Gooderham MJ. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. Int J Dermatol 2022; 61: 746-754.
https://doi.org/10.1111/ijd.15853 DOI: https://doi.org/10.1111/ijd.15853
Nogueira M, Torres T. Janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib. Dermatol Pract Concept 2021; 11: e2021145.
https://doi.org/10.5826/dpc.1104a145 DOI: https://doi.org/10.5826/dpc.1104a145
Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol 2021; 35: 1797-1810.
https://doi.org/10.1111/jdv.17351 DOI: https://doi.org/10.1111/jdv.17351
Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis. Dermatol Ther 2022; 35: e15636.
https://doi.org/10.1111/dth.15636 DOI: https://doi.org/10.1111/dth.15636
Correia C, Antunes J, Filipe P. Management of acne induced by JAK inhibitors. Dermatol Ther 2022; 35: e15688.
https://doi.org/10.1111/dth.15688 DOI: https://doi.org/10.1111/dth.15688
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 2022; 386: 1687-1699.
https://doi.org/10.1056/NEJMoa2110343 DOI: https://doi.org/10.1056/NEJMoa2110343
Guo L, Feng S, Sun B, Jiang X, Liu Y. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol 2020; 34: 192-201.
https://doi.org/10.1111/jdv.15937 DOI: https://doi.org/10.1111/jdv.15937
Awad SM, Tawfik YM, El-Mokhtar MA, El-Gazzar AF, Abdel Motaleb AA. Activation of Janus kinase signaling pathway in acne lesions. Dermatol Ther 2021; 34: e14563.
https://doi.org/10.1111/dth.14563 DOI: https://doi.org/10.1111/dth.14563
Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, Clements A, et al. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol 2014; 55: 250-254.
https://doi.org/10.1111/ajd.12124 DOI: https://doi.org/10.1111/ajd.12124
Aydingoz IE, Tukenmez Demirci G, Agirbasli D, Oz-Arslan D, Yenmis G. The investigation of the amounts and expressions of epidermal growth factor, epidermal growth factor receptor, and epidermal growth factor receptor gene polymorphisms in acne vulgaris. J Cosm Dermatol 2021; 20: 346-351.
https://doi.org/10.1111/jocd.13498 DOI: https://doi.org/10.1111/jocd.13498
Dréno B, Dagnelie MA, Khammari A, Corvec S. The skin microbiome: a new actor in inflammatory acne. Am J Clin Dermatol 2020; 21: 18-24.
https://doi.org/10.1007/s40257-020-00531-1 DOI: https://doi.org/10.1007/s40257-020-00531-1
Mias C, Mengeaud V, Bessou-Touya S, Duplan H. Recent advances in understanding inflammatory acne: deciphering the relationship between cutibacterium acnes and Th17 inflammatory pathway. J Eur Acad Dermatol Venereol 2023; 37: 3-11.
https://doi.org/10.1111/jdv.18794 DOI: https://doi.org/10.1111/jdv.18794
Dagnelie MA, Montassier E, Khammari A, Mounier C, Corvec S, Dréno B. Inflammatory skin is associated with changes in the skin microbiota composition on the back of severe acne patients. Exp Dermatol 2019; 28: 961-967.
https://doi.org/10.1111/exd.13988 DOI: https://doi.org/10.1111/exd.13988
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Fabienne Ballanger, Nicole Auffret, Marie-Thérèse Leccia, Jean Paul Claudel, Brigitte Dréno
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
